COVID-19 Antibody Study: The Canadian Partnership for Tomorrow’s Health (CanPath) - CanPath - Canadian Partnership for Tomorrow’s Health

CanPath – Canadian Partnership for Tomorrow’s Health Search

About Us
- Purpose, Vision & Mission
  CanPath is working in partnership to prevent disease and provide a platform for scientists to conduct innovative research.
- Our History
  The Canadian Partnership Against Cancer established the Canadian Partnership for Tomorrow Project (now CanPath) in June 2008.
- Leadership & Governance
  Meet the members of CanPath's Leadership Team, Operations Committee, National Strategic Advisory Council and more.
- National Coordinating Centre
  Meet the members of CanPath's operational core, based at the University of Toronto's Dalla Lana School of Public Health.
- Regional Cohorts
  Seven regional cohorts across ten provinces comprise CanPath's pan-Canadian partnership.
- Funders & Supporters
  Learn more about the partner organizations that provide funding and in-kind support to CanPath.
- Frequently Asked Questions
  Find out how CanPath will improve the health of Canadians and more.
- Contact us
  How to reach CanPath by phone, email, in-person, or make a data access request.
Research
- About the Study
  CanPath is Canada’s largest population health cohort and a gateway platform to data worldwide.
- Access Process
  The CanPath Access Portal provides researchers with the necessary resources to identify epidemiological and biological data available from participating cohorts to answer innovative research questions.
- Approved Projects & Studies
  CanPath has supported more than 100 research projects and activities, many of which have resulted in publications in high impact journals.
- Publications
  These publications are examples of research made possible with data from CanPath and its regional cohorts.
- Funding & Grant Opportunities
- COVID-19 Initiatives
  As Canada’s largest population health study, CanPath responded quickly to the pandemic by leveraging its existing infrastructure to support national COVID-19 research.
- Student Dataset
  CanPath's Student Dataset provides students the unique opportunity to gain hands-on experience working with CanPath data.
- Collaborations
  The CanPath team is committed to collaborating with partners in order to enhance and accelerate research for a healthier Canada.
Participants
- About the Study
  CanPath is Canada’s largest population health cohort and a gateway platform to data worldwide.
- Participant Snapshot
  Understand the unique social, economic and health characteristics of CanPath participants and how this information is captured for research.
- Meet CanPath Participants
  Hundreds of thousands of Canadians have come together to be part of a study that reveals real breakthroughs.
- COVID-19 Antibody Study FAQ
  CanPath and its regional cohorts are conducting a COVID-19 antibody study of 20,000 participants across Canada.
News & Events
CanPath Access Portal

COVID-19 Antibody Study: The Canadian Partnership for Tomorrow’s Health (CanPath)

Principal Investigator: Dr. Victoria Kirsh

Affiliation: Ontario Institute for Cancer Research

Start Year: 2021

CanPath is conducting a COVID-19 Antibody Study. Participants are asked to complete an online questionnaire and provide a dried blood spot sample using a kit mailed to their home. The study is under way in all six regional CanPath cohorts. The questionnaire includes details around vaccination (vaccine availability, willingness to receive the COVID-19 vaccine, and vaccination status, along with brand name and date received), previous COVID-19 infection (suspected only, or lab confirmed along with date of positive test), and underlying medical conditions diagnosed in the past year and medications taken. Dried blood spot samples are being tested for three antibodies to COVID-19. Two of these represent an immune response to either prior infection or vaccine and the third represents an immune response to prior infection only. We will determine whether immune response varies by brand of vaccine (Pfizer-BioNTech, Moderna, AstraZeneca), whether older individuals exhibit a weaker immune response and whether pre-conditions, medical treatments, or host genetics affect immune response. We will also assess the direction and strength of the immune response over time. With the majority of Canadians having received only a single vaccine dose, variation in immune response by type of vaccine has important implications for current public health guidance. Also, it will be important to monitor individuals with pre-conditions and or medical treatments to determine how treatment impacts the development of immunity over time, and to determine whether vaccine efficacy changes as new variants emerge.